Quantcast

Latest Trazodone Stories

4809a5a530001ec159a1b0d285aed72d
2011-08-04 06:45:00

Antidepressant use and the risk of adverse outcomes in older people: population-based cohort study New generation antidepressants, known as selective serotonin reuptake inhibitors (SSRIs) are associated with an increased risk of several severe adverse outcomes in older people compared with older tricyclic antidepressants (TCAs), finds a study published in the British Medical Journal on August 3. The authors say the risks and benefits of different antidepressants should be carefully evaluated...

2011-04-25 16:38:32

Scientists at the Fisher Center for Alzheimer's Disease Research at The Rockefeller University, led by Paul Greengard, Ph.D., and Jennifer Warner-Schmidt, Ph.D., have shown that anti-inflammatory drugs, which include ibuprofen, aspirin and naproxen, reduce the effectiveness of the most widely used class of antidepressant medications, the selective serotonin reuptake inhibitors, or SSRIs, taken for depression and obsessive-compulsive disorder and anxiety disorders. This surprising discovery,...

2011-01-25 07:00:00

PRINCETON, N.J., Jan. 25, 2011 /PRNewswire/ -- Angelini Labopharm, LLC, today confirmed Mary Anne Heino's appointment as President of the Company. Formerly Senior Vice President, Sales and Marketing for Labopharm Inc. and President of the company's wholly owned subsidiary, Labopharm USA, Inc., Ms. Heino's primary focus will be to leverage the Angelini Labopharm joint venture for the commercialization of OLEPTRO(TM), as well as to explore opportunities for line-extensions and the...

2011-01-20 08:46:00

- Company Advancing Partnership Discussions and Preparing for Canadian Launch - LAVAL, QC, Jan. 20 /PRNewswire/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that Health Canada's Therapeutic Products Directorate (TPD) has approved OLEPTRO(TM) (trazodone hydrochloride Extended Release Tablets), a novel once-daily formulation of the antidepressant trazodone, for the symptomatic relief of Major Depressive Disorder (MDD) in adults. OLEPTRO(TM) acts as a serotonin antagonist reuptake...

2010-11-23 00:01:06

OLEPTROâ“ž¢ Data Presented at U.S. Psychiatric and Mental Health Congress OLEPTROâ“ž¢ Offers Physicians a Treatment Alternative for Patients with Major Depressive Disorder Princeton, NJ (Vocus) November 22, 2010 This week at the 2010 U.S. Psychiatric and Mental Health Congress in Orlando, FL, Angelini Labopharm presented two analyses from the pivotal clinical trial for OLEPTROâ“ž¢ (trazodone...

2010-11-19 00:00:42

Media Advisory ** Interview Opportunity Princeton, NJ (Vocus) November 18, 2010 Major depressive disorder (MDD) is a common mental illness that affects more than 14 million American adults. It can seriously impact every area of a person's life and, if left untreated, can lead to disability, dependency and even suicide. OLEPTROâ“ž¢ (trazodone hydrochloride) extended-release tablets were launched in August of this year as a treatment for MDD in adults. Two...

2010-11-12 06:20:00

LAVAL, QC, Nov. 12 /PRNewswire/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that on November 11, 2010 it received notice from Actavis South Atlantic LLC advising that Actavis has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval to market 150 and 300 mg generic versions of OLEPTRO(TM) (trazodone hydrochloride extended-release 150 and 300 mg tablets) in the United States. Under the Drug Price Competition...

2010-08-10 08:00:00

LAVAL, QC, Aug. 10 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of...

2010-08-10 07:45:00

PRINCETON, N.J., Aug. 10 /PRNewswire/ -- Angelini Labopharm today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, is now commercially available in the United States. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related